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INTRODUCTION
It is well known that cardiovascular disease is the number
one cause of death among patients with end-stage renal dis-
ease (1). In Korea, cardiovascular disease accounted for over
30% of the 1,256 overall deaths among dialysis patients in
2005 (2). However, cardiovascular risk is not limited to end-
stage renal disease, and risk of cardiovascular mortality begins
to increase with even mild impairment of kidney function
(3, 4). This increased risk of cardiovascular mortality in patients
with chronic kidney disease (CKD) seems to be caused by non-
traditional risk factors such as anemia, altered calcium phos-
phorus metabolism, inflammation and oxidative stress, as well
as traditional risk factors such as hypertension, smoking, dia-
betes, dyslipidemia and left ventricular hypertrophy (5).
Most studies showing an association between kidney func-
tion and mortality have assessed renal function by measuring
only serum creatinine without an estimate of the glomerular
filtration rate (eGFR) (6, 7) or have provided a rough cate-
gorization of renal function based on the eGFR (8). Further-
more, in previous studies patients were not stratified by the
severity of coronary artery disease (CAD) to determine the
independent effect of renal function on mortality. Therefore,
a graded relationship between cardiovascular risk and eGFR
needs to be defined after adjustment for the severity of CAD.
High prevalence of coronary artery plaques in dialysis patients
has been documented (9, 10). However, few prior studies have
examined the direct association between coronary anatomy
and CKD that does not require dialysis. One meta-analysis
suggested that there was no association (11), while some other
studies suggested there was a relationship (12, 13). It is impor-
tant to explore whether the severity of CKD is associated with
the severity of CAD.
The optimal therapeutic modality in CKD patients with
CAD has not been defined. Despite established awareness of
high cardiovascular risk in CKD patients, these patients enco-
unter “therapeutic nihilism”, in which there is a lack of appro-
priate medication and intervention (14). Some retrospective
analyses showed improved long-term survival and reduced
rates of repeated revascularization procedures by using a coro-
nary artery bypass graft (CABG) rather than percutaneous coro-
nary intervention (PCI) in patients with CKD (15-17). Alth-
ough long-term mortality is increased, it appears that the
results of PCI in CKD patients are now comparable to the
results in the general population (18). It is important to inves-
tigate the clinical outcomes of CKD patients with CAD across
treatment strategies. Moreover, the efficacy of drug-eluting
stents for the treatment of CAD in CKD patients remains
unproven.
The purpose of this study is to investigate the relationship
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The Association between Kidney Function, Coronary Artery Disease,
and Clinical Outcome in Patients Undergoing Coronary Angiography
To characterize the association between chronic kidney disease (CKD), mortality,
severity of coronary artery disease (CAD), treatment modality of CAD, and type of
coronary stents among patients undergoing coronary angiography (CAG), we ret-
rospectively reviewed the electronic medical records of the patients who underwent
CAG at Seoul National University Bundang Hospital in Korea between May 2003
and January 2006. CKD was staged using an estimated glomerular filtration rate
(eGFR) from the creatinine value prior to CAG. There were 3,637 patients included.
The presence of CAD was 48% in CKD stage 1, 61% in stage 2, 73% in stage 3,
87% in stage 4, and 81% in stage 5. Survival rate gradually diminished for patients
with decreasing renal function. No significant differences in all-cause and cardiac
mortality were observed by medical treatment, PCI or CABG, in CKD patients with
an eGFR less than 60 mL/min/1.73 m
2. CKD patients with drug-eluting stents showed
significantly lower all-cause mortality (5.4% vs. 13.3%) and incidence of myocardial
infarction (1.7% vs. 10%) than those with bare metal stents. In conclusion, an eGFR
is a strong independent prognostic marker among patients undergoing CAG and
the severity of CAD increases progressively with worsening renal function.
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Accepted : 11 November 2008between renal function and clinical outcome among patients
undergoing coronary angiography (CAG), using categorized
adjustments in the classification of renal function according
to CKD stage in compliance with the National Kidney Foun-
dation K/DOQI guidelines (19). In addition, we investigat-
ed whether CKD stage affected severity in the pathology of
CAD. Finally, we evaluated the clinical outcomes of CKD
patients with an eGFR less than 60 mL/min/1.73 m2 strati-
fied according to treatment modality and type of stent.
MATERIALS AND METHODS
Patients
The electronic medical records of patients who underwent
CAG for the evaluation of CAD at Seoul National Universi-
ty Bundang Hospital in Korea between May 2003 and Jan-
uary 2006 were retrospectively reviewed. Patients with valvu-
lar heart disease, congenital heart disease, or cardiomyopa-
thy were excluded from this analysis. 
Data collection and outcomes
Clinical characteristics at the time of CAG were collected:
a number of clinical risk factors, including age, sex, smoking,
and the presence of the following medical conditions: hyper-
tension, dyslipidemia, cerebrovascular disease, peripheral vas-
cular disease, congestive heart failure, diabetes, and prior my-
ocardial infarction. Laboratory data and current medications
were also reviewed. The presence of regional wall motion abnor-
mality was determined, and left ventricular ejection fraction
(EF) was measured by echocardiography. The extent of vessel
disease was defined by the number of major coronary arteries
with luminal narrowing ≥50% by visual estimation. Major
coronary arteries included left anterior descending artery, left
circumflex artery, and right coronary artery. Assignment to
either PCI or CABG was made on the basis of the initial revas-
cularization procedure after CAG. Patients whose initial treat-
ment did not include either PCI or CABG were referred to
medical therapy. The primary clinical outcome of this study
was all-cause mortality. Major adverse cardiac events (MACE),
such as restenosis at a follow-up CAG, myocardial infarction,
or target vessel revascularization (TVR), were also examined.
Subgroup analysis was also performed for patients with an
eGFR less than 60 mL/min/1.73 m2. In these patients, clin-
ical outcomes were compared depending on the treatment
modality or the type of stent implanted.
Assessment of renal function
The most recent creatinine measurement prior to CAG was
used (average, 31.7±91.8 days). Renal function was calcu-
lated by the simplified Modification of Diet in Renal Disease
(MDRD) equation (20) and categorized according to CKD
stage in compliance with the National Kidney Foundation
K/DOQI guidelines (19). Patients in CKD stage 1 had nor-
mal renal function. Patients with CKD indicated those
belonged to CKD stage 3, 4, and 5 with an eGFR less than
60 mL/min/ 1.73 m2.
Equation was as follows.
eGFR (mL/min/1.73 m2)=186×creatinine-1.154 (μ M/L)×
age
-0.203 (×0.742, if women; ×1.21, if black).
Statistical analysis
The clinical characteristics of the patients are presented as
mean±SD for continuous variables and as percentages for
categorical variables. ANOVA and chi-square analyses were
performed for continuous and categorical variables, respec-
tively. pvalue less than 0.05 were considered statistically sig-
nificant. Survival time was calculated from the date of CAG
to the date on which the data were censored or all-cause mor-
tality occurred. Data were censored if follow-up ended or the
patient was still alive at the end of the study. The cumulative
survival rates in each CKD stage were estimated by the Kaplan-
Meier method, and the differences in survival rates between
stages were evaluated by log-rank (Mantle-Cox) method. Cox
proportional hazards analysis was used to determine the effect
of renal function on survival after adjusting for other risk fac-
tors. Variables univariately associated with the outcome (p<
0.05) were entered into the multivariable model using step-
wise selection. Statistical analyses were performed using SPSS
(version 15.0. for Windows; SPSS Inc, Chicago, IL, U.S.A.).
RESULTS
Baseline characteristics
Three thousand, seventy hundred thirty eight cases of CAG
were performed during this period. Ninety seven cases were
repeated CAGs in the same patients. Four patients had no
measurement of serum creatinine. A total of 3,637 patients
were included in this analysis. Baseline clinical characteristics
are shown in Table 1. Of all the patients included, 1,102 pa-
tients belonged to CKD stage 1 with normal renal function,
1,632 patients were in stage 2, 838 were in stage 3, 61 were
in stage 4, and 104 patients were in stage 5. In total, 27.6%
of the patients were included in CKD stages 3/4/5 with an
eGFR less than 60 mL/min/1.73 m2. Compared with patients
with normal renal function, patients with CKD were older,
more often female, and more likely to have comorbid medi-
cal conditions such as hypertension, cerebrovascular disease,
peripheral vascular disease, congestive heart failure, diabetes,
and prior myocardial infarction. In the echocardiographic find-
ings, more frequent regional wall motion abnormality and
lower left ventricular EF were observed as renal function wors-
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lower hemoglobin, lower albumin, and lower cholesterol lev-
els. However, C-reactive protein level increased as CKD stage
increased. Among patients with normal renal function, 68.2%
were managed medically, 27.8% underwent PCI, and only
4% were treated with CABG. As the severity of CKD inc-
reased, PCI and CABG were chosen more often than medical
treatment. Erythropoietin, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, and β - blockers were
prescribed more frequently to the patients in CKD stages
4/5 than to the patients in CKD stages 1/2.
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*p value represents differences across categories of kidney function.
RWMA, regional wall motion abnormality; EF, ejection fraction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACEIs,
angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
CKD stage (eGFR mL/min/1.73 m
2)
Variable p value* 12 3 4 5
(≥90) (89-60) (59-30) (29-15) (< 15 or dialysis)
(n=1,002) (%) (n=1,632) (%) (n=838) (%) (n=61) (%) (n=104) (%)
Age (yr) 58.9±11.5 62.3±12.4 67.3±11.0 71.1±10.4 66.3±10.2 <0.001
Male 83.6 57.4 25.9 39.3 59.6 <0.001
Hypertension 50.7 54.7 63.8 78.7 77.9 <0.001
Hypercholesterolemia 22.3 22.9 19.0 13.1 13.5 0.017
Cerebrovascular disease 5.6 5.1 7.5 3.3 16.3 <0.001
Peripheral vascular disease 2.2 2.1 2.9 8.2 9.6 <0.001
Congestive heart failure 1.3 2.0 2.7 3.3 8.7 <0.001
Diabetes 24.3 25.1 33.5 68.9 60.6 <0.001
Smoking 24.6 36.9 41.3 26.2 24.0 <0.001
Prior myocardial infarction 6.6 7.5 9.8 9.8 10.6 0.084
RWMA 21.1 22.9 33.9 44.9 38.3 <0.001
Echocardiographic EF (%) 59.6±9.6 58.0±10.5 55.1±12.5 52.4±14.4 53.3±11.9 <0.001
Hemoglobin (g/dL) 13.4±1.6 13.9±1.8 13.6±2.1 11.0±2.2 10.7±2.0 <0.001
Albumin (g/dL) 4.0±0.3 4.1±0.3 3.9±0.4 3.6±0.5 3.5±0.5 <0.001
Total cholesterol (mg/dL) 191.9±41.7 193.9±41.6 188.7±47.9 168.2±38.6 171.3±52.1 <0.001
C-Reactive protein (mg/dL) 0.98±2.99 0.85±2.50 1.56±3.64 1.12±2.18 2.91±5.43 <0.001
Treatment <0.001
Medical 68.2 62.7 50.8 36.1 51.0
PCI 27.8 32.2 39.9 45.9 37.5
CABG 4.0 5.1 9.3 18.0 11.5
Medication
Erythropoietin 0 0 0.4 6.6 66.3 <0.001
ACEIs or ARBs 30.2 30.0 37.7 49.2 79.8 <0.001
β -blockers 33.2 31.9 34.5 42.6 71.2 <0.001
Statins 22.6 23.7 20.6 21.3 22.1 0.568
Table 1. Baseline characteristics
*p value represents differences across categories of kidney function; 
� Insignificnat disease defined as a lesion with <50% luminal narrowing; 
� Left main
disease indicated a significant narrowing of the left main coronary artery.
CKD stage (eGFR mL/min/1.73 m
2)
Variable p value* 123 45
(≥90) (89-60) (59-30) (29-15) (< 15 or dialysis)
(n=1,002) (%) (n=1,632) (%) (n=838) (%) (n=61) (%) (n=104) (%)
Number of involved coronary arteries
Insignificant disease
� 51.9 39.3 27.2 13.1 19.2
One vessel disease 20.5 23.2 17.9 18.0 18.3
Two vessel disease 14.4 17.5 24.5 18.0 26.0
Three vessel disease 13.3 20.0 30.4 50.8 36.5
Presence of coronary arterial lesion 48.1 60.7 72.8 86.9 80.8 <0.001
Left main disease
� 8.7 9.0 8.6 13.1 14.4 0.263
Table 2. Angiographic dataAngiographic features
The presence of CAD with involvement of more than one
vessel was 48% in CKD stage 1, 61% in stage 2, 73% in stage
3, 87% in stage 4, and 81% in stage 5 (Table 2). A signifi-
cant tendency for the presence of CAD was revealed as eGFR
declined. Although the effects were not statistically signifi-
cant across patients in different CKD stages, three-vessel dis-
ease and left main disease seemed to be more frequent in pa-
tients in CKD stages 4/5 than those in CKD stage 1/2.
Clinical outcomes
Fig. 1 shows the survival curve of the patients by stage of
CKD. Mean duration of follow-up in theses patients was eleven
months. Survival rate was greatest for patients with normal
renal function and gradually decreased for patients with decreas-
ing renal function. A Cox stepwise multivariate analysis showed
that high CKD stage, old age, presence of diabetes, low serum
albumin level and high number of involved coronary arteries
were independent predictors of all-cause mortality (Table 3).
Risk of death increased more than six-fold in patients with
stage 5, more than three-fold in patients with stage 4, and
2.5-fold in patients with stage 3 as compared to patients with
normal renal function. Stage 2 CKD seemed to be associat-
ed with increasing risk of mortality, but the relationship did
not reach statistical significance as an independent predictor.
Clinical outcomes stratified according to each treatment
modality in CKD patients with an eGFR less than 60 mL/
min/1.73 m2 were evaluated (Table 4). PCI was done in 401
patients, CABG was done in 101 patients, and 501 patients
received medical treatment only. No significant differences
in all-cause and cardiac mortality were observed among these
three groups. The frequency of MACE, including restenosis
and TVR, was statistically higher in the PCI and CABG groups
than in the medical treatment group.
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*Reference CKD stage 1; 
� Reference insignificnat disease; 
� Adjusted with
age, gender, history of diabetes mellitus, history of congestive heart fail-
ure, history of any malignant neoplasm, history of previous coronary heart
disease, BMI, mean arterial blood pressure, hemoglobin, calcium, phos-
phorus, uric acid, cholesterol, serum albumin, urine proteinuria 1+ or
more by dipstick test, C-Reactive Protein, number of diseased coronary
artery, treatment with erythropoietin, type of coronary stent, treatment
modality of coronary arterial lesion, CKD stage.
Variable Relative risk (95% C.I.)
� p value
CKD stage*
Stage 2 1.465 (0.675-3.182) 0.335
Stage 3 2.506 (1.152-5.450) 0.02
Stage 4 3.145 (1.134-8,725) 0.028
Stage 5 6.032 (2.596-14.015) <0.001
Age (per 1 yr) 1.050 (1.027-1.074) <0.001
Diabetes 1.685 (1.070-2.655) 0.024
Serum albumin level 0.371 (0.220 -0.626) <0.001
(per 1.0 g/dL increase)
Number of involved coronary 1.288 (1.045-1.587) 0.018
arteries
�
Table 3. Multivariate predictors of all-cause mortality
PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft; MACE, major adverse cardiovascular event; TVR, target vessel
revascularization.
Medical PCI CABG
treatment (n=401) (n=101) p value
(n=501) (%) (%) (%)
All-cause mortality 6.2 8.7 5.0 0.228
Cardiac mortality 3.4 5.5 1.0 0.075
MACE 1.9 11.4 11.5 <0.001
Restenosis 3.4 21.0 8.6 <0.001
Myocardial infarction 0.8 3.3 4.9 0.058
TVR 1.1 10.4 8.2 <0.001
Table 4. Univariate analysis of clinical outcomes in patients with
eGFR <60 mL/min/1.73 m
2 by management strategy used
MACE, major adverse cardiovascular event; TVR, target vessel revas-
cularization.
Bare metal stent Drug eluting stent
p value
(n =60) (%) (n =312) (%)
All-cause mortality 13.3 5.4 0.025
Cardiac mortality 6.7 3.8 0.324
MACE 14.0 11.6 0.643
Restenosis 26.5 20.6 0.364
Myocardial infarction 10.0 1.7 0.003
TVR 10.0 11.1 0.819
Table 5. Univariate analysis of clinical outcomes in patients with
eGFR <60 mL/min/1.73 m
2 treated with drug eluting or bare metal
stents
Fig. 1. Kaplan-Meier survival curves for all-cause mortality by chron-
ic kidney disease (CKD) stages.
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CKD stage 5Next, we investigated whether the type of stent used affect-
ed clinical outcomes in CKD patients with an eGFR less than
60 mL/min/1.73 m2 (Table 5). In this group of patients, drug-
eluting stents were implanted much more frequently than
bare metal stents (312 vs. 60). CKD patients with drug-elut-
ing stents showed significantly lower rates of all-cause mor-
tality than those with bare metal stents (5.4% vs. 13.3%).
However, there were no statistically significant differences by
type of stent for cardiac mortality. For MACE, only the inci-
dence of myocardial infarction was significantly less frequent
in the drug-eluting stents group than in the bare metal stents
group (1.7% vs. 10%). 
DISCUSSION
We characterized the severity of CAD and clinical outcome
according to the degree of kidney function based on the data
from more than 3,600 patients. Our results revealed that pa-
tients with the higher-stage CKD had more severe CAD and
worse clinical outcomes than those in the lower stages of CKD.
CKD stage was the strongest predictor of all-cause mortali-
ty in patients who underwent CAG. Treatment with PCI or
CABG was associated with more adverse cardiovascular events
than medical treatment in CKD patients with an eGFR less
than 60 mL/min/1.73 m2. In this group of patients, drug-elut-
ing stents significantly reduced all-cause mortality and recur-
rence of myocardial infarction as compared with bare metal
stents.
From the baseline characteristics of the more than 3,600
patients in this study, patients with decreased renal function
tended to have more comorbid medical conditions and more
severe cardiac dysfunction. These findings are consistent with
previous studies (5, 16, 21). This clustering of significant
cardiovascular risk factors and comorbidities in CKD patients
likely contributed to the severity of CAD and elevated mor-
tality. Lower hemoglobin levels in CKD stages 4/5 patients
seemed to be caused by reduced production of erythropoietin
as renal function deteriorates. High C-reactive protein in our
CKD patients suggests a proinflammatory state, which is
associated with increased cardiovascular risk (22, 23). The
laboratory findings in this study might represent an associa-
tion between non-traditional cardiovascular risk factors and
poor outcomes in CKD (24, 25). Erythropoietin was prescribed
to our CKD patients due to renal anemia. Some studies report-
ed that CKD patients with CAD showed a tendency for aspirin,
β -blockers and statins to be underused, probably due to con-
cerns about limited efficacy and toxic effects in renal dysfunc-
tion (26, 27). However, angiotensin-converting enzyme inhi-
bitors, angiotensin receptor blockers, and β -blockers were
more frequently prescribed in our CKD patients, so we can
at least exclude the possibility of worse clinical outcomes in
CKD due to inadequate use of medications.
There were reports showing an increase in rates of CAD in
the presence of CKD (12, 13), but the sample size was small,
and both studies were conducted on selected populations. Addi-
tionally, it has been reported that patients with non-dialysis-
dependent CKD have more severe coronary lesions than those
with normal kidney function (28). However, this finding might
reflect selection bias because dialysis patients were less like-
ly to have severe coronary anatomy than those with non-dial-
ysis-dependent CKD. Chonchol et al. (29) recently reported a
significant relationship between CKD and angiographic CAD
in 261 male patients with positive nuclear imaging studies.
They also showed that CKD patients were more likely to
have three-vessel or left main disease. In contrast to our study,
their study cohort included only males and neglected many
important cardiovascular risk factors. In this study, we com-
pared the angiographic findings of more than 3,600 patients,
including over 1,000 CKD patients with an eGFR less than
60 mL/min/1.73 m2. We found that the severity of CAD was
directly proportional to the degree of renal dysfunction, and
CKD patients have a high prevalence of angiographic CAD.
Our results support the findings showing a strong associa-
tion between cardiovascular mortality and CKD (4).
Although variables such as age, diabetes, serum albumin
level, and number of involved coronary arteries are indepen-
dent predictors of mortality in our population, CKD stage is
the strongest predictor. Possible explanations for the increased
mortality rate associated with CKD include increased tradi-
tional and non-traditional cardiovascular risk factors in these
patients, and increased complications from cardiovascular
disease when it develops. Despite the increased risk profile of
our CKD patients prior to CAG, CKD was independently
associated with mortality even after adjusting for these vari-
ables. Our results are consistent with previous studies (16, 26,
30). There are also some reports showing a graded inverse rela-
tionship between renal function and risk of death (31, 32).
Furthermore, renal insufficiency is an independent predictor
of increased in-hospital morbidity and mortality after PCI
with stent implantation (33). Even after successful PCI, CKD
was associated with increased short-term and long-term mor-
tality (19, 34). According to our data and those of others, eGFR
is a strong prognostic marker independent of underlying sever-
ity of CAD in patients with cardiovascular disease. Therefore,
the systemic ascertainment of renal function in all patients
with cardiovascular disease should be encouraged.
Most patients with renal dysfunction and acute coronary
syndrome have been treated medically rather than by percu-
taneous or surgical revascularization (21, 35). However, more
than half of our CKD patients with an eGFR less than 60 mL/
min/1.73 m2 underwent PCI or CABG. The inception point
of this study was CAG. Therefore, all the patients who pre-
sented with stable angina as well as acute coronary syndrome
were included. The optimal treatment strategy with regard
to CAD in CKD patients is controversial. Several studies have
suggested that CABG is better than or similar to PCI in the
clinical outcomes of patients on dialysis (15, 36-38). Subgroup
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trial showed that mild to moderate CKD patients with an
eGFR around 50 mL/min who were randomly assigned to
CABG or PCI showed similar outcomes for both treatments
(39, 40). However, Keeley et al. showed that PCI has a bet-
ter survival rate than CABG or medical treatment for patients
with severe CKD and acute coronary syndrome (21). Since
cardiac interventions did not worsen long-term renal func-
tion (41), more aggressive management of the increased car-
diovascular risk in CKD patients should be encouraged. The
reason that a certain treatment modality did not provide a
survival benefit over another treatment in our CKD patients
may stem from the short follow-up period for detecting the
differences. Another possible explanation is that the treatments
were not randomly assigned; our results might also be biased
by the treatment preferences of our hospital.
The recent introduction of drug-eluting stents has dramat-
ically decreased the incidence of restenosis and the need for
repeat revascularization (42, 43). Previous studies showed that
CKD patients had a higher mortality after PCI with bare metal
stents than patients with normal renal function, with no dif-
ference in the rates of repeat revascularization (18, 33, 37, 44).
The superiority of drug-eluting stents has yet to be established
in patients with CKD (45-48). Although there were no dif-
ferences in the rates of restenosis or TVR, our study showed
that drug-eluting stents significantly reduced the rate of all-
cause mortality and myocardial infarction. We propose that
more frequent use of drug-eluting stents should be recom-
mended to improve the long-term outcomes in patients with
renal dysfunction.
Despite the comprehensive nature of this data, there are
several limitations to consider in this study. First, our patients
are only those who underwent CAG. These patients are a sub-
set of all patients with cardiovascular disease and may not reflect
the outcomes of all patients with cardiovascular disease. Sec-
ond, we defined CKD stage based on an eGFR derived from
a single serum creatinine determination rather than on a serum
creatinine determination on the day of CAG or a direct mea-
surement of renal function, like iothalamate clearance. In addi-
tion, the creatinine value might have been influenced by med-
ications or clinical status. Third, indication bias might have
affected the results because the indication for treatment may
affect the outcomes. For example, if the presence of CKD influ-
ences choice of treatment modality, it may introduce a bias
that may also affect clinical outcomes. Fourth, clinical out-
come data in patients with an eGFR less than 60 mL/min/
1.73 m2 were based on univariate analysis. Further prospec-
tive randomized trials are required. Fifth, due to the obser-
vational nature of this study, it is not possible to determine
a causal relationship between renal function and mortality
among patients undergoing CAG. Final limitations include
the single-center experience represented by these data.
In summary, we found that among patients undergoing
CAG, there is a direct relationship between renal dysfunction
and risk of mortality, independent of underlying clinical risk
factors. We also showed that the severity of CAD increased
progressively with decreasing renal function. In CKD patients,
drug-eluting stents showed more favorable clinical outcomes
than did bare metal stents.
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